The Power of Radiotherapy

The Specificity of Molecular Targeting

for Better
Patient Outcomes

Because Cancer Patients
Need a New Approach

Commitment

Andarix Pharmaceuticals is developing and commercializing novel cancer therapies that are targeted to the patients most likely to respond. Tozaride, our lead product entering Phase 2 clinical trials, targets specific cancers at the molecular level, and its companion diagnostic  identifies the patients with the corresponding molecular signature who are the best candidates for therapy.

commitment

Targeted Therapies
for Personalized Medicine

Peptide targeted radiotherapy is a promising new approach to cancer therapy and has been widely validated in clinical studies as well as in routine clinical use in Europe. Treating cancer with radiotherapy can achieve results not possible with conventional therapies because cancer cells are unable to evade the lethal damage caused by targeted radiation.

News & Events

Andarix Pharmaceuticals to Present at the Metals to Medicine Gordon Research Conference

Jul 20, 2018

Targeting Lung Cancer in Rare Disease Patient Populations SOMERVILLE, MA— June 25, 2018 — Andarix Pharmaceuticals, a clinical stage company aimed at developing a targeted peptide therapies for hard to treat cancers, announced today that it will present a poster at the Metals in Medicine Gordon Research Conference .The conference will take place June 25-29…

Read More

Andarix Pharmaceuticals to Present at the Rare Disease Innovation Summit

Jul 19, 2018

Targeting Lung Cancer in Rare Disease Patient Populations SOMERVILLE, MA— June 19, 2018 — Andarix Pharmaceuticals, a clinical stage company aimed at developing targeted peptide therapies for hard to treat cancers, announced today that its Chief Executive Officer, Chris Adams, will present at the Rare Disease Innovation Summit set to take place in Cambridge ,…

Read More

Andarix Pharmaceuticals to Present at Chinese Biopharmaceutical Association Conference, USA

Jul 18, 2018

Expanding Opportunities in Asia SOMERVILLE, MA— June 9, 2018 — Andarix Pharmaceuticals, a clinical stage company aimed at developing targeted peptide therapies for hard to treat cancers, announced that its Chief Executive Officer, Chris Adams, will present at the Chinese Biopharmaceutical Association (CBA) USA conference. The CBA conference will take place on June 9, 2018…

Read More